Biotech Values

[DFRAI]

Perhaps BMY needs a little ZIOP

In Preclinical studies IL12 + anti PD1 at 15mg results in 100% survival at day 80.

Controlled tumor IL-12 production was able to
stimulate the immune system in the presence of innate
tumor immunosuppression
• The addition of anti-PD-1 therapy resulted in a
reduction in tumor innate immunosuppression
• The combination of both therapies resulted in
decreased immunosuppression coupled with local
immunostimulation proved to be beneficial in the
treatment of glioma with a profound increase in
survival over controls & monotherapy
• Clinical study design to assess combination
therapy in recurrent GBM in progress

Ziop is starting phase 1 this year in combo above

http://ziopharm.com/content/02-pipeline/03-presentations-publications/3-asgct/1-regulated-expression-of-il-12-as-gene-therapy-concomitant-with-blockade-of-pd-1-for-treatment-of-glioma/asgct2016re.pdf